2,4,6-Trifluorophenol | CAS:2268-17-9

We serve 2,4,6-Trifluorophenol CAS:2268-17-9 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
2,4,6-Trifluorophenol

Chemical Name:2,4,6-Trifluorophenol
CAS.NO:2268-17-9
Synonyms:2,4,6-Trifluorophenol
2,4,6-trifluoro-phenol
Phenol,2,4,6-trifluoro
Molecular Formula:C6H3F3O
Molecular Weight:148.08300
 
Physical and Chemical Properties:
Density:1.473
Melting point:49-51ºC
Boiling point:128.1ºC
Flash point:55.1ºC
Index of Refraction:1.471
 
Specification:
Appearance:White to off-white solid
Assay:≥97.0%
Moisture:≤0.2%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Organic synthesis intermediate



Contact us for information like 2,4,6-Trifluorophenol chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Phenol,2,4,6-trifluoro physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Phenol,2,4,6-trifluoro Use and application,Phenol,2,4,6-trifluoro technical grade,usp/ep/jp grade.


Related News: More serious cases could lead to potentially deadly conditions such as pneumonia and kidney failure, with the former having been reported among some patients in China.4,6-Dibromodibenzofuran manufacturer Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders.3-Methylbenzoic acid supplier Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders.N-(5H-Purin-6-yl)benzamide vendor Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders.Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders.